Cargando…

Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells

Our results show that using an EBV-LCL feeder cell line, large numbers of pure populations of highly activated NK cells can be expanded ex vivo under GMP conditions. With the exception of thyroiditis and constitutional symptoms related to IL-2 therapy, infusions of up to 1 x 10(8) cells/kg of ex viv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lundqvist, Andreas, Berg, Maria, Smith, Aleah, Childs, Richard W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2011
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133963/ https://www.ncbi.nlm.nih.gov/pubmed/21750690

Ejemplares similares

Bortezomib sensitizes human glioblastoma stem cells to adoptive natural killer cell cytotoxicity
por: Grossenbacher, Steven, et al.
Publicado: (2015)

An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells
por: Lieberman, Nicole A. P., et al.
Publicado: (2018)

Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy
por: GRANZIN, MARKUS, et al.
Publicado: (2015)

Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion
por: Allan, David S.J., et al.
Publicado: (2021)

Potent ex vivo expanded, human CD34+ cord blood-derived natural killer cells for cancer immunotherapy
por: Zhang, Xiaokui, et al.
Publicado: (2015)

Real-Time Tracking of Ex Vivo-Expanded Natural Killer Cells Toward Human Triple-Negative Breast Cancers
por: Uong, Tung Nguyen Thanh, et al.
Publicado: (2018)

Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer
por: Choi, Jung-Won, et al.
Publicado: (2019)

Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses
por: Earl, Patricia L., et al.
Publicado: (2020)

Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia
por: Sarkar, Debalina, et al.
Publicado: (2014)

Autologous cellular therapy for myeloma: Giving ex vivo expanded NK cells their due
por: Shapiro, Roman M., et al.
Publicado: (2022)

Autologous NK cells propagated and activated ex vivo decrease senescence markers in human PBMCs
por: Chelyapov, Nickolas, et al.
Publicado: (2022)

Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors
por: Shida, Yoichi, et al.
Publicado: (2021)

Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation
por: Granzin, Markus, et al.
Publicado: (2017)

Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo
Publicado: (1985)

Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2016)

Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro
por: Tanaka, Yoshitaka, et al.
Publicado: (2019)

Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells
por: Luna, Jesus I., et al.
Publicado: (2019)

Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
por: Chen, Chen, et al.
Publicado: (2017)

Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma
por: Chu, Yaya, et al.
Publicado: (2020)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Stem cells out of the bag: characterization of ex vivo expanded mesenchymal stromal cells for possible clinical use
por: Lopes, Sérgio M, et al.
Publicado: (2020)

Toxoplasma gondii-infected natural killer cells display a hypermotility phenotype in vivo
por: Ueno, Norikiyo, et al.
Publicado: (2015)

A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
por: Nguyen, Rosa, et al.
Publicado: (2019)

Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions
por: Jung, Daun, et al.
Publicado: (2021)

Suppression of Glomerulonephritis in NZB/NZW Lupus Prone Mice by Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells
por: Scalapino, Kenneth J., et al.
Publicado: (2009)

Cyclosporine A but Not Corticosteroids Support Efficacy of Ex Vivo Expanded, Adoptively Transferred Human Tregs in GvHD
por: Landwehr-Kenzel, Sybille, et al.
Publicado: (2021)

Increased Motility and Suppression of Ex Vivo–Expanded Regulatory T Cells Designed for Adoptive Transfer Therapy in Ulcerative Colitis
por: Müller, Tanja M., et al.
Publicado: (2023)

Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells
por: Vahedi, Fatemeh, et al.
Publicado: (2017)

Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma
por: Kisseberth, William C., et al.
Publicado: (2021)

Natural killer cells in antitumour adoptive cell immunotherapy
por: Laskowski, Tamara J., et al.
Publicado: (2022)

Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial
por: Gao, Yao, et al.
Publicado: (2021)

In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma
por: Matera, Lina, et al.
Publicado: (2006)

Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo
por: Stanton, Sasha E., et al.
Publicado: (2016)

Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy
por: Kang, Lin, et al.
Publicado: (2013)

Ex Vivo Expansion of Highly Cytotoxic Natural Killer Cells Using Optimal Culture Medium
por: Kim, Seokho
Publicado: (2022)

Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
por: Lupo, Kyle B., et al.
Publicado: (2019)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
por: Denman, Cecele J., et al.
Publicado: (2012)

Migration, Distribution, and Safety Evaluation of Specific Phenotypic and Functional Mouse Spleen-Derived Invariant Natural Killer T2 Cells after Adoptive Infusion
por: Chen, Dongzhi, et al.
Publicado: (2021)

Safety and feasibility study of ex vivo expanded allogeneic-NK cells infusion in patients with acute pneumonia caused by COVID-19
por: Ahmadvand, Mohammad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3e0lrk16qnsb6612bob182g61p